Guardant Health, Inc. (GH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 232,088 | 203,471 | 191,476 | 177,235 |
| Cost of precision oncology testing | - | - | 66,095 | 65,715 |
| Cost of development services and other | - | - | 8,394 | 6,706 |
| Sales and marketing expense | 119,588 | 104,316 | 97,880 | 81,867 |
| Research and development expense | 87,449 | 88,521 | 87,306 | 83,102 |
| General and administrative expense | 50,259 | 46,952 | 49,129 | 40,463 |
| Cost of revenue | 81,205 | 74,723 | - | - |
| Total costs and operating expenses | 338,501 | 314,512 | 308,804 | 277,853 |
| Loss from operations | -106,413 | -111,041 | -117,328 | -100,618 |
| Interest income | 7,560 | 9,112 | 13,257 | 13,913 |
| Interest expense | 983 | 791 | 646 | 645 |
| Other income (expense), net | -25 | 7,851 | -3,007 | -15,145 |
| Loss before provision for income taxes | -99,861 | -94,869 | -107,724 | -102,495 |
| Provision for income taxes | 38 | 290 | 30 | 133 |
| Net loss | -99,899 | -95,159 | -107,754 | -102,628 |
| Net loss per share, basic (in usd per share) | -0.8 | -0.77 | -0.88 | -0.84 |
| Net loss per share, diluted (in usd per share) | -0.8 | -0.77 | -0.88 | -0.84 |
| Weighted-average shares used in computing net loss per share, basic (in shares) | 124,114,000 | 123,871,000 | 123,051,000 | 122,447,000 |
| Weighted-average shares used in computing net loss per share, diluted (in shares) | 124,114,000 | 123,871,000 | 123,051,000 | 122,447,000 |